A vaccine with an overall efficacy rate of 90.4% and a 93.2% efficacy against variants of interest and concern, developed by US biotechnology company Novavax, is expected to arrive in the country in the third quarter of the year. The vaccine’s trade name in the Philippines is CovovaxTM
Tag: covovax
Millions of Filipinos stand to benefit from CovovaxTM promising results.
Philippine CovovaxTM distributor Faberco Life Sciences, citing the results released by Novavax in the US, today said that the vaccine provides 100 % protection against severe cases of COVID 19 and 96.4 percent efficacy against original strain of COVID-19.